Source: MarketScreener

Imstem Biotechnology: AgeX Therapeutics' Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001

(marketscreener.com) ImStem's MSC Product Candidate IMS001 is Derived from AgeX's Pluripotent Stem Cell Line ESI-053 https://www.marketscreener.com/quote/stock/AGEX-THERAPEUTICS-INC-47382002/news/AgeX-Therapeutics-Licensee-ImStem-Biotechnology-Announces-First-U-S-Multiple-Sclerosis-Patient-Dos-37167294/?utm_medium=RSS&utm_content=20211130

Read full article »

Imstem Biotechnology's Competitors | Imstem Biotechnology's News | Imstem Biotechnology's Financials

Followers on Owler

Est. Annual Revenue

$100K-5.0M

Est. Employees

1-25

CEO

Rami Levin

CEO Approval Rating

90/100

Imstem is a Connecticut-based biotechnology company that develops and commercializes stem cell based regenerative cellular therapies for the treatment of serious diseases.